AAP
RLAY icon

Arax Advisory Partners’s Relay Therapeutics RLAY Stock Holding History

Arax Advisory Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.26K Buy
227
+208
+1,095% +$1.86K ﹤0.01% 3076
2025
Q4 		$161 Sell
19
-15,038
-100% -$107K ﹤0.01% 3756
2025
Q3 		$78.6K Buy
+15,057
New +$57.4K ﹤0.01% 1630
2024
Q4 		– Sell
-372
Closed -$2.63K – 2691
2024
Q3 		$2.63K Sell
372
-666
-64% -$4.98K ﹤0.01% 1957
2024
Q2 		$6.77K Buy
+1,038
New +$7.09K ﹤0.01% 1451

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Arax Advisory Partners's RLAY Position: Q1 2026 in Review

Arax Advisory Partners increased its Relay Therapeutics (RLAY) stake by 1,095% in Q1 2026, buying an estimated $1.86K and bringing the position to 227 shares worth $2.26K. The position accounts for ﹤0.01% of the portfolio, ranked #3076.

Arax Advisory Partners first reported a position in RLAY in Q2 2024 and has held it in 5 quarters since. The position peaked at $78.6K in Q3 2025. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Arax Advisory Partners held 227 shares of Relay Therapeutics worth $2.26K as of Q1 2026.
  • Arax Advisory Partners bought 208 Relay Therapeutics shares in Q1 2026, an estimated $1.86K.
  • Relay Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3076 holding.
  • Arax Advisory Partners first reported a position in Relay Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Relay Therapeutics position peaked at $78.6K in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.